Non-invasive Advantage Position Hemolens Diagnostics as a non-invasive coronary artery disease diagnostic leader offering faster, less costly, and more accurate screening to reduce unnecessary invasive angiographies and shorten patient pathway.

Global Recognition Leverage recent awards such as Masters of Global Impact and technology adoption accolades to open conversations with health systems, insurers, and procurement teams emphasizing credibility and validated impact.

Qualified Market Target mid to large healthcare providers and diagnostic networks in regions with rising CAD burden, focusing on countries where Hemolens has local visibility or prior recognition to accelerate pilot programs.

Growth Readiness Highlight scalable tech stack and cross-disciplinary team to reassure buyers about integration with existing IT, security standards, and potential for rapid deployment within hospital IT ecosystems.

Funding Signals Use revenue range and awards to craft messaging around market traction and ROI potential, proposing pilot studies, contract-based pricing, and value-based procurement to convert interest into signed deals.